Read More 1 minute read Analyst Ratings News Price Target B of A Securities Maintains Neutral on Cintas, Raises Price Target to $400 By vishwanath@benzinga.com Today, 7:27 AM B of A Securities analyst Gary Bisbee maintains Cintas (NASDAQ:CTAS) with a Neutral and raises the price target from $383 to $400. CTAS
Read More 1 minute read Analyst Ratings News Price Target Upgrades Wolfe Research Upgrades Cabot Oil & Gas to Outperform, Raises Price Target to $28 By vishwanath@benzinga.com Today, 7:27 AM Wolfe Research analyst Josh Silverstein upgrades Cabot Oil & Gas (NYSE:COG) from Peer Perform to Outperform and raises the price target from $25 to $28. COG
Read More 1 minute read Analyst Ratings News Upgrades Kepler Cheuvreux Upgrades Pearson to Hold By vishwanath@benzinga.com Today, 7:27 AM Kepler Cheuvreux analyst Conor O'Shea upgrades Pearson (NYSE:PSO) from Reduce to Hold. PSO
Read More 1 minute read Analyst Ratings News Price Target Cowen & Co. Maintains Outperform on ArcBest, Raises Price Target to $115 By vishwanath@benzinga.com Today, 7:27 AM Cowen & Co. analyst Jason Seidl maintains ArcBest (NASDAQ:ARCB) with a Outperform and raises the price target from $99 to $115. ARCB
Read More 1 minute read Analyst Ratings News Price Target Roth Capital Maintains Buy on A-Mark Precious Metals, Raises Price Target to $72 By vishwanath@benzinga.com Today, 7:27 AM Roth Capital analyst Andrew Scutt maintains A-Mark Precious Metals (NASDAQ:AMRK) with a Buy and raises the price target from $60 to $72. AMRK
Read More 1 minute read Analyst Ratings News Price Target Craig-Hallum Maintains Buy on Asbury Automotive Group, Raises Price Target to $250 By vishwanath@benzinga.com Today, 7:27 AM Craig-Hallum analyst Ryan Sigdahl maintains Asbury Automotive Group (NYSE:ABG) with a Buy and raises the price target from $230 to $250. ABG
Read More 1 minute read Analyst Ratings News Price Target SVB Leerink Maintains Market Perform on Acceleron Pharma, Raises Price Target to $180 By vishwanath@benzinga.com Today, 7:27 AM SVB Leerink analyst Geoffrey Porges maintains Acceleron Pharma (NASDAQ:XLRN) with a Market Perform and raises the price target from $148 to $180. XLRN
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Underweight on Office Props IT, Lowers Price Target to $22 By vishwanath@benzinga.com Today, 7:27 AM Morgan Stanley analyst Ronald Kamdem maintains Office Props IT (NASDAQ:OPI) with a Underweight and lowers the price target from $24 to $22. OPI
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Overweight on Highwoods Properties, Raises Price Target to $49 By vishwanath@benzinga.com Today, 7:27 AM Morgan Stanley analyst Ronald Kamdem maintains Highwoods Properties (NYSE:HIW) with a Overweight and raises the price target from $48 to $49. HIW
Read More 1 minute read Analyst Ratings News Price Target Morgan Stanley Maintains Equal-Weight on Cintas, Lowers Price Target to $365 By vishwanath@benzinga.com Today, 7:27 AM Morgan Stanley analyst Toni Kaplan maintains Cintas (NASDAQ:CTAS) with a Equal-Weight and lowers the price target from $368 to $365. CTAS